- Leverages Poseida s proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid tumors -
TOKYO and SAN DIEGO, May 1, 2024 /PRNewswire/ Astellas.
Permanent J-code J2782 effective April 1, 2024
NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ Iveric Bio, An Astellas Company , today announced the U.S. Centers for Medicare and Medicaid Services.
Global retina expert joins to support sozinibercept development and launch preparationMELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor. An internationally recognized retina specialist and clinical scientist, Dr. Khanani i